Forma Therapeutics. has filed a patent for solid forms of a specific compound. The claim mentions cancellation of claims 1-20. GlobalData’s report on Forma Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData


Data Insights Forma Therapeutics Inc - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Forma Therapeutics, Cancer treatment biomarkers was a key innovation area identified from patents. Forma Therapeutics's grant share as of January 2024 was 46%. Grant share is based on the ratio of number of grants to total number of patents.

Solid forms of a specific chemical compound

Source: United States Patent and Trademark Office (USPTO). Credit: Forma Therapeutics Inc

The patent application (Publication Number: US20240033261A1) discloses a solid form of Compound 1, characterized by specific X-ray Powder Diffraction (XRPD) patterns and differential scanning calorimetry (DSC) thermograms. The solid form exhibits peaks at precise d-spacing and 2 theta angles, along with an endothermic event at approximately 256.6°C. Additionally, the patent describes an oral unit dosage form containing the solid form of Compound 1, along with various excipients such as fillers, disintegrants, lubricants, and glidants.

The oral unit dosage form detailed in the patent application includes specific amounts of the solid form of Compound 1 and excipients, with variations in total dosage ranging from 50-150 mg. The excipients mentioned, such as microcrystalline cellulose, croscarmellose sodium, colloidal silicon dioxide, and magnesium stearate, play crucial roles in the formulation. The patent also outlines the relative weight ratio of Compound 1, filler, disintegrant, and lubricant in the oral dosage unit, emphasizing a specific composition for optimal performance. These claims provide a detailed insight into the solid form of Compound 1 and its application in an oral unit dosage form, highlighting the importance of specific XRPD patterns and excipient composition for pharmaceutical formulations.

To know more about GlobalData’s detailed insights on Forma Therapeutics, buy the report here.

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies